Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variables

Front Immunol. 2023 May 15:14:1115536. doi: 10.3389/fimmu.2023.1115536. eCollection 2023.

Abstract

In the development of cell-based cancer therapies, quantitative mathematical models of cellular interactions are instrumental in understanding treatment efficacy. Efforts to validate and interpret mathematical models of cancer cell growth and death hinge first on proposing a precise mathematical model, then analyzing experimental data in the context of the chosen model. In this work, we present the first application of the sparse identification of non-linear dynamics (SINDy) algorithm to a real biological system in order discover cell-cell interaction dynamics in in vitro experimental data, using chimeric antigen receptor (CAR) T-cells and patient-derived glioblastoma cells. By combining the techniques of latent variable analysis and SINDy, we infer key aspects of the interaction dynamics of CAR T-cell populations and cancer. Importantly, we show how the model terms can be interpreted biologically in relation to different CAR T-cell functional responses, single or double CAR T-cell-cancer cell binding models, and density-dependent growth dynamics in either of the CAR T-cell or cancer cell populations. We show how this data-driven model-discovery based approach provides unique insight into CAR T-cell dynamics when compared to an established model-first approach. These results demonstrate the potential for SINDy to improve the implementation and efficacy of CAR T-cell therapy in the clinic through an improved understanding of CAR T-cell dynamics.

Keywords: CAR T-cells; SINDy; allee effect; antigen binding; cell therapy; dynamical systems; glioblastoma; latent variables.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Cell Death
  • Cell Line, Tumor
  • Humans
  • Immunotherapy, Adoptive / methods
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes*

Substances

  • Receptors, Chimeric Antigen